NCT06625827View on ClinicalTrials.gov

A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

January 22, 2024

Study Completion Date

January 22, 2024

Conditions

Healthy

Interventions

DRUG

Digoxin

Oral administration

DRUG

Nemtabrutinib

Oral administration

Trial Locations (1)

66219

ICON (Site 0001), Lenexa

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY